Estimate | B | s.e | 95% CI | B | s.e | 95% CI |
---|
Intercept | 47.52 | 0.98 | [45.82, 49.23] | 9804 | 867 | [8181, 11557] |
Group | − 1.39 | 1.39 | [− 3.76, 0.92] | − 980 | 1233 | [− 3451, 1448] |
T1 | − 9.09 | 0.84 | [− 10.74, − 7.54] | 66 | 754 | [− 1085, 1236] |
T1*Group | − 3.87 | 1.19 | [− 6.12, − 1.64] | − 467 | 1072 | [− 2340, 1411] |
T2 | − 0.47 | 0.87 | [− 1.96, 1.07] | 502 | 793 | [− 1107, 2131] |
T2*Group | − 0.09 | 1.23 | [− 2.31, 2.13] | − 729 | 1118 | [− 2979, 1473] |
T1*Group + T2*Group | − 3.96 | 1.23 | [− 6.62, − 1.32] | − 1196 | 1110 | [− 3550, 1256] |
- 95% CI: Bootstrapped 95% confidence interval. GSRS-IBS: Gastrointestinal Symptom Rating Scale—IBS version
- The estimates are from bootstrapped piecewise mixed models regression analyses of GSRS-IBS scores and total costs, including intervention costs. The T1 and T2 variables denote the time from pre-treatment to post-treatment and from post-treatment to 6-month follow-up, respectively. The T1 and T2 interaction effects with the Group variable denote the differential developments over time between the study groups during these two time periods. The summed interaction effect is the cumulative difference in change between pre-treatment to 6-month follow-up